GlassScriptPhysician profile
Mark A Kuriata
NPI 1033220637
$1,528.41
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $180 · 2021: $450 · 2022: $108 · 2023: $15.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $674.39 | 2019-2023 | |
| Janssen Biotech, INC. | $157.92 | 2019-2021 | |
| Lilly USA, LLC | $149.13 | 2019-2022 | |
| Abbvie INC. | $120.50 | 2019-2021 | |
| Almirall LLC | $112.98 | 2019-2021 | |
| Amgen INC. | $61.94 | 2021 | |
| Sun Pharmaceutical Industries INC. | $56.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $47.54 | 2019-2021 | |
| Celgene Corporation | $41.28 | 2019 | |
| Pfizer INC. | $27.75 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.87 | 2019 | |
| Biofrontera INC. | $17.83 | 2021 | |
| Prugen, INC. Pharmaceuticals | $15.10 | 2019 | |
| Genzyme Corporation | $13.13 | 2020 | |
| Allergan, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kuriata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.